S.M.V. is an independent director at IMV, and a consultant for Fed Bio and Kanvas Biosciences. D.D. receives institutional grants and research support from Arcus, Immunocore, Merck, Regeneron Pharmaceuticals and Tesaro/GSK; is a consultant for ACM Bio, Ascendis, Castle, Clinical Care Options, Gerson Lehrman Group, Immunitas, Medical Learning Group, Replimmune, Trisalus and Xilio Therapeutics; a member of the speakers’ bureau for Castle Biosciences; and is involved in the US Patent 63/124,231 (‘Compositions and Methods for Treating Cancer’) and US Patent 63/208,719 (‘Compositions and Methods For Responsiveness to Immune Checkpoint Inhibitors (ICI), Increasing Effectiveness of ICI and Treating Cancer’).